Celldex Therapeutics, Inc. (CLDX) vs Pharvaris N.V. (PHVS)
A side-by-side comparison of Celldex Therapeutics, Inc. and Pharvaris N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$31.02HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
PHVS
Pharvaris N.V.
$30.75HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — CLDX vs PHVS
growth of $100 · dividends reinvested · last 6yCLDX +51.4% (+7.2%/yr)PHVS +5.1% (+0.8%/yr)CLDX compounded faster over this window
CLDX PHVS
CLDX vs PHVS: by the numbers
- •PHVS is the larger company ($2.15B vs $2.06B market cap).
- •Both run net losses; PHVS's is the smaller (0.00% vs -268385.71% net margin).
Metrics side by side
Valuation
| Metric | CLDX | PHVS |
|---|---|---|
| P/S ratio | 18428.78 | N/A |
| P/B ratio | 2.89 | 6.25 |
Profitability
| Metric | CLDX | PHVS |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -19160.00% | 0.00% |
| Net margin | -268385.71% | 0.00% |
| ROE | -42.07% | -57.96% |
| ROIC | -45.19% | -61.74% |
Growth (annualized)
| Metric | CLDX | PHVS |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | N/A |
| Total return CAGR (5Y) | -10.28% | 11.45% |
Frequently asked
- How have CLDX and PHVS total returns compared?
- Over the past 5 years, CLDX delivered -10.28% and PHVS delivered 11.45% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.